Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
766.14-
QQQ
715.040.24%
BTC/USD
78307.870.3225%
DIA
532.000.08%
GLD
405.000.84%
TLT
81.850.43%

Silence Therapeutics PLC

SLNNASDAQ
Trade with Public
Trade with Public
$13.53
0.110.82%
At close: Aug 28, 5:00 PM EST
$13.53
0.110.82%
Pre-Market: 4:01 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentCompareOptionsStock Report

Silence Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Silence Therapeutics (SLN).

Price Target Range — 11 Quarters

Analyst Consensus — 6 Analysts

5Buy
1Sell
Consensus RatingBuy# Analysts6Avg. Consensus PT$41Upside to Avg. PT+201.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 11, 2026Morgan StanleyMichael UlzPT RaiseOverweight$25→$32
Jun 24, 2026Cantor FitzgeraldPrakhar AgrawalInitiateOverweight—
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Silence Therapeutics, Raises Price Target to $32

Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and raises the price target from $25 to $32.
Benzinga Newsdesk

This $300 Million Biotech May Be Deeply Mispriced: Analyst

Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major catalyst in the PV market.
Vandana Singh

PRO
Cantor Fitzgerald Initiates Coverage On Silence Therapeutics with Overweight Rating

Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Silence Therapeutics (NASDAQ:SLN) with a Overweight rating.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 price target.
Benzinga Newsdesk

Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data

Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh divesiran's profile against rusfertide.
Vandana Singh

PRO
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved